Skip to content
naulon
Not checkedNot checked for notices yet.

A pathogenic variant in the transforming growth factor beta I (TGFBI) in four Iranian extended families segregating granular corneal dystrophy type II: A literature review

Aliasgar Mohammadi, Aazam Ahmadi Shadmehri, Mahnaz Taghavi and 3 more

Iranian Journal of Basic Medical Sciences · 2020

doi:10.22038/ijbms.2020.36763.8757 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<em><strong>Objective(s):</strong></em> Granular and lattice corneal dystrophies (GCDs & LCDs) are autosomal dominant inherited disorders of the cornea. Due to genetic heterogeneity and large genes, unraveling the mutation is challenging.<br /><em><strong>Materials and Methods:</strong></em> Patients underwent comprehensive clinical examination, and targeted next-generation sequencing (NGS) was used for mutation detection. Co-segregation and in silico analysis was accomplished.<br /><em><strong>Results:</strong></em> Patients suffered from GCD. NGS disclosed a known pathogenic variant, c.371G>A (p.R124H), in exon 4 of TGFBI. The variant co-segregated with the phenotype in the family. Homozygous patients manifested with more severe phenotypes. Variable expressivity was observed among heterozygous patients. <br /><em><strong>Conclusion:</strong></em> The results, in accordance with previous studies, indicate that the c.371G>A in TGFBI is associated with GCD. Some phenotypic variations are related to factors such as modifier genes, reduced penetrance and environmental effects.

Abstract licence: CC BY-NC

References64

    40 more references, whose wording the paper’s licence keeps private.

    All 64 references

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.